<DOC>
	<DOCNO>NCT00117130</DOCNO>
	<brief_summary>The purpose study evaluate subject preference Aranesp® administer monthly ( i.e. , every 4 week ( Q4W ) ) Procrit® administer weekly ( QW ) .</brief_summary>
	<brief_title>Study Evaluate Effectiveness Aranesp®</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects must sign write informed consent Be Procrit® QW Q2W minimum 12 week Must currently stable dose Procrit® ( define less 25 % change Procrit® dose 4 week period immediately prior enrollment , missed dos ) Have Hgb 1012 g/dL least 4 week prior study start Have 15 less GFR less 89 mL/min/1.73 m2 Have serum vitamin B12 folate level low limit normal Transferrin saturation great 20 % Currently receive investigational erythropoietic agent Expected initiate renal replacement therapy ( dialysis transplantation ) within 1 year study start Have le 1 year life expectancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Kidney disease , Renal , CKD ( Chronic Kidney Disease )</keyword>
	<keyword>CRI ( Chronic Renal Insufficiency ) , Pre-dialysis , Amgen</keyword>
	<keyword>Aranesp® , Darbepoetin alfa , QW dose</keyword>
	<keyword>Q2W dosing , Q4W dose</keyword>
	<keyword>Patient preference , Subject preference</keyword>
</DOC>